During a five-year trial of canakinumab, patients with systemic juvenile idiopathic arthritis taking canakinumab showed progress toward clinical remission and glucocorticoid tapering…
FDA Approves Subcutaneous Tocilizumab for Ages 2–17
The FDA has approved subcutaneous tocilizumab for treating active systemic juvenile idiopathic arthritis in pediatric patients as young as 2 years old…
Gene Expression Signature Useful for Diagnosing Kawasaki Disease
NEW YORK (Reuters Health)—A 13-transcript whole-blood gene expression signature accurately differentiates Kawasaki disease (KD) from other febrile conditions in children, researchers report. “We believe it is feasible to turn the signature into a diagnostic test,” Dr. Michael Levin from Imperial College London, London, tells Reuters Health by email. “There are a range of methods to…
Rituximab Use Increasing in Treatment of Pediatric Vasculitis
According to a large cohort study of pediatric patients, rituximab use is on the rise in the treatment of children diagnosed with vasculitis. Treatment with cyclophosphamide remains common, but it’s beginning to wane. Dialysis and mechanical ventilation also remain common, the study indicates. The retrospective study of hospitalized children in the U.S. included the largest…
How to Recognize, Diagnose Periodic Fever Syndromes in Adults
A number of autoinflammatory syndromes that result from genetic mutations have been described recently. The vast majority occur in children. However, three periodic fever syndromes are important for rheumatologists who treat adults to know about. The goal of this review is to provide a concise description of each condition, and to help the clinician understand…
Tocilizumab a “First Choice” for PHID Syndrome
NEW YORK (Reuters Health)—Tocilizumab should be the “first choice” for treatment of the autoinflammatory and cutaneous manifestations of pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome, say clinicians from the U.K. PHID syndrome is an extremely rare autosomal recessive genetic disease caused by mutations in the SLC29A3 gene. Children with the syndrome develop patches…
Biosimilar Infliximab Appears Safe, Effective in Pediatric IBD
NEW YORK (Reuters Health)—A biosimilar version of infliximab appears as effective as the original for treating pediatric inflammatory bowel disease (PIBD), and less costly, new research shows. “These baseline data have now enabled us to confidently switch patients from originator to biosimilar, adopting the same prospective methodology to monitor effectiveness, safety and cost,” Dr. Lisa…
Fulbright Scholar Researches Physical Activity in Swedish Children with Juvenile Idiopathic Arthritis
A stroll through downtown Stockholm presents a quintessential picture of an active community, with most people biking or walking as their preferred mode of travel. Yet children in Sweden who live with juvenile idiopathic arthritis (JIA)—currently estimated at around 64 of every 100,000—don’t always engage in this active lifestyle.1 Maura Daly Iversen, PT, DPT, SD,…
Adalimumab + Methotrexate Effective for Uveitis in JIA
Research has found that taking adalimumab plus methotrexate is effective for patients with juvenile idiopathic arthritis-associated uveitis. However, these patients may also experience an increased incidence of adverse and serious adverse events compared with those taking only methotrexate…
Help Pediatric Patients Overcome Pain & Anxiety
Pediatric rheumatology patients present unique challenges. According to Kyla Driest, MD, MEd, using age and temperament appropriate methods, such as distraction or icing, may help children manage pain and ease anxiety…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »